Progenics Pharmaceuticals, Inc.  

(Public, NASDAQ:PGNX)   Watch this stock  
Find more results for PGNX
5.92
-0.09 (-1.50%)
After Hours: 5.92 0.00 (0.00%)
Jul 25, 4:00PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.89 - 6.18
52 week 3.61 - 11.15
Open 6.01
Vol / Avg. 1.48M/1.91M
Mkt cap 404.00M
P/E     -
Div/yield     -
EPS -0.59
Shares 69.95M
Beta 2.07
Inst. own 88%
Aug 4, 2016
Q2 2016 Progenics Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Aug 4, 2016
Q2 2016 Progenics Pharmaceuticals Inc Earnings Call - 8:30AM EDT - Add to calendar
Jul 13, 2016
Progenics Pharmaceuticals Inc at Cantor Fitzgerald Healthcare Conference
Jun 9, 2016
Progenics Pharmaceuticals Inc at Jefferies Healthcare Conference
May 5, 2016
Q1 2016 Progenics Pharmaceuticals Inc Earnings Release
May 5, 2016
Q1 2016 Progenics Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -517.27% -450.89%
Operating margin -519.02% -453.02%
EBITD margin - -446.51%
Return on average assets -40.30% -26.77%
Return on average equity -60.15% -36.32%
Employees 66 -
CDP Score - -

Address

777 Old Saw Mill River Rd
TARRYTOWN, NY 10591-6717
United States - Map
+1-914-7892800 (Phone)
+1-914-7892817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company's EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces an automated Bone Scan Index quantification. The Company's clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ([18F] DCFPyL), 1095 and PSMA ADC. The Company's partnered products include Relistor-Subcutaneous injection, Relistor-Oral Tablets and PRO 140.

Officers and directors

Peter J. Crowley Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Mark R. Baker J.D. Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Patrick Fabbio Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Nitya G. Ray Ph.D. Senior Vice President - Manufacturing
Age: 62
Bio & Compensation  - Reuters
Vivien Wong Ph.D. Senior Vice President - Operations and Portfolio Management
Age: 58
Bio & Compensation  - Reuters
Ann Marie Assumma Vice President - Regulatory Affairs
Age: 61
Bio & Compensation  - Reuters
Karen J. Ferrante M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Michael D. Kishbauch Independent Director
Age: 66
Bio & Compensation  - Reuters
David A. Scheinberg MD., Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Nicole S. Williams Independent Director
Age: 70
Bio & Compensation  - Reuters